Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Nilay Shah, MD

Advertisement

Articles by Nilay Shah, MD

Nilay Shah, MD

Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

ByNilay Shah, MD
September 28th 2022

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Advertisement

Latest Updated Articles

  • Nilay Shah, MD
    Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

    September 28th 2022



Advertisement
Advertisement

Trending on OncLive

1

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

2

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

3

Hematologists Highlight Top Data From ASCO 2026

4

Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS

5

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us